Global Dermatomyositis Treatment Market

Dermatomyositis Treatment Comprehensive Study by Dermatomyositis Type (Classic Dermatomyositis (CDM), Amyopathic Dermatomyositis (ADM), Hypomyopathic Dermatomyositis (HDM), Other), Age Group (Children, Adults), Medication Type (Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent), Non-Pharmacotherapy (General Therapeutic Measures, Surgery)), End User (Hospitals, Research & Development Institutes, Other) Players and Region - Global Market Outlook to 2030

Dermatomyositis Treatment Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.54%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Dermatomyositis Treatment
Dermatomyositis (DM) is a rare autoimmune condition that affects children and adults and is one of the many idiopathic inflammatory myopathies (IIM) with cutaneous involvement (predominately affects the skin and muscles). Dermatomyositis may occur at any time from infancy through approximately age 80, but most commonly it occurs between ages 40 to 60. The estimated incidence of dermatomyositis is 9.63 cases per million people. In children, the symptoms usually appear between the ages of five to 15 years. Approximately three in 1,000,000 children are affected by juvenile dermatomyositis. Females are affected by dermatomyositis twice as often as males. The growing dermatomyositis cases worldwide has increased the demand for dermatomyositis treatment.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR5.54%


The key players are increasingly focusing on the development of new and advanced treatments or drugs for dermatomyositis or several inflammatory diseases. Players are also targeting partnerships and mergers as their business strategies to enter into the market or strengthen their portfolio and overall growth of the company. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Dermatomyositis Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Ranbaxy Laboratories Limited (India), Abbott Laboratories (United States), Sanofi S.A. (France), Cipla Limited (India), Actelion Pharmaceuticals Ltd. (Switzerland) and Corbus Pharmaceuticals Holdings, Inc. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Dermatomyositis Treatment market by and Region.



On the basis of geography, the market of Dermatomyositis Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Dermatomyositis Type, the sub-segment i.e. Classic Dermatomyositis (CDM) will boost the Dermatomyositis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Age Group, the sub-segment i.e. Children will boost the Dermatomyositis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Medication Type, the sub-segment i.e. Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent) will boost the Dermatomyositis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospitals will boost the Dermatomyositis Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Skin And Muscles Diseases Among Adults

Market Growth Drivers:
Increasing Prevalence of Dermatomyositis Cases Globally and Dermatomyositis Treatment Suitability for Patient of Any Age

Challenges:
Limited Adoption in Undeveloped Areas

Restraints:
High Cost of Dermatomyositis Treatment

Opportunities:
Regulatory Support for Dermatomyositis Treatment and Untapped Emerging Countries

Market Leaders and their expansionary development strategies
In June 2022, Pfizer and Roivant Sciences announced the unveiling of a clinical-stage biotechnology company, Priovant Therapeutics to develop therapies for patients with autoimmune disease. The newly launched company is developing oral brepocitinib for the treatment of dermatomyositis and lupus which is a dual inhibitor of TYK2 and JAK1 and has potential to provide efficacy in multiple highly inflammatory autoimmune diseases.
In July 2021, Octapharma's Octagam received approval from FDA for the treatment of adults with dermatomyositis. FDA has approved Octagam based on positive results of the ProDERM study. ProDERM trial included a 16-week phase in which 78.7% of patients who received 10% Octagam positively responded to the treatment as compared to the patients who received a placebo.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Dermatomyositis Treatment Provider, Healthcare Institutes, Venture Capitalists and Private Equity Firms and Government Regulatory and Research Organizations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Dermatomyositis Type
  • Classic Dermatomyositis (CDM)
  • Amyopathic Dermatomyositis (ADM)
  • Hypomyopathic Dermatomyositis (HDM)
  • Other

By Age Group
  • Children
  • Adults

By Medication Type
  • Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent)
  • Non-Pharmacotherapy (General Therapeutic Measures, Surgery)

By End User
  • Hospitals
  • Research & Development Institutes
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Dermatomyositis Cases Globally
      • 3.2.2. Dermatomyositis Treatment Suitability for Patient of Any Age
    • 3.3. Market Challenges
      • 3.3.1. Limited Adoption in Undeveloped Areas
    • 3.4. Market Trends
      • 3.4.1. Increasing Skin And Muscles Diseases Among Adults
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dermatomyositis Treatment, by Dermatomyositis Type, Age Group, Medication Type, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Dermatomyositis Treatment (Value)
      • 5.2.1. Global Dermatomyositis Treatment by: Dermatomyositis Type (Value)
        • 5.2.1.1. Classic Dermatomyositis (CDM)
        • 5.2.1.2. Amyopathic Dermatomyositis (ADM)
        • 5.2.1.3. Hypomyopathic Dermatomyositis (HDM)
        • 5.2.1.4. Other
      • 5.2.2. Global Dermatomyositis Treatment by: Age Group (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
      • 5.2.3. Global Dermatomyositis Treatment by: Medication Type (Value)
        • 5.2.3.1. Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent)
        • 5.2.3.2. Non-Pharmacotherapy (General Therapeutic Measures, Surgery)
      • 5.2.4. Global Dermatomyositis Treatment by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Research & Development Institutes
        • 5.2.4.3. Other
      • 5.2.5. Global Dermatomyositis Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Dermatomyositis Treatment (Price)
  • 6. Dermatomyositis Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ranbaxy Laboratories Limited (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi S.A. (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cipla Limited (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Actelion Pharmaceuticals Ltd. (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Corbus Pharmaceuticals Holdings, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
  • 7. Global Dermatomyositis Treatment Sale, by Dermatomyositis Type, Age Group, Medication Type, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Dermatomyositis Treatment (Value)
      • 7.2.1. Global Dermatomyositis Treatment by: Dermatomyositis Type (Value)
        • 7.2.1.1. Classic Dermatomyositis (CDM)
        • 7.2.1.2. Amyopathic Dermatomyositis (ADM)
        • 7.2.1.3. Hypomyopathic Dermatomyositis (HDM)
        • 7.2.1.4. Other
      • 7.2.2. Global Dermatomyositis Treatment by: Age Group (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
      • 7.2.3. Global Dermatomyositis Treatment by: Medication Type (Value)
        • 7.2.3.1. Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent)
        • 7.2.3.2. Non-Pharmacotherapy (General Therapeutic Measures, Surgery)
      • 7.2.4. Global Dermatomyositis Treatment by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Research & Development Institutes
        • 7.2.4.3. Other
      • 7.2.5. Global Dermatomyositis Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Dermatomyositis Treatment (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dermatomyositis Treatment: by Dermatomyositis Type(USD Million)
  • Table 2. Dermatomyositis Treatment Classic Dermatomyositis (CDM) , by Region USD Million (2018-2023)
  • Table 3. Dermatomyositis Treatment Amyopathic Dermatomyositis (ADM) , by Region USD Million (2018-2023)
  • Table 4. Dermatomyositis Treatment Hypomyopathic Dermatomyositis (HDM) , by Region USD Million (2018-2023)
  • Table 5. Dermatomyositis Treatment Other , by Region USD Million (2018-2023)
  • Table 6. Dermatomyositis Treatment: by Age Group(USD Million)
  • Table 7. Dermatomyositis Treatment Children , by Region USD Million (2018-2023)
  • Table 8. Dermatomyositis Treatment Adults , by Region USD Million (2018-2023)
  • Table 9. Dermatomyositis Treatment: by Medication Type(USD Million)
  • Table 10. Dermatomyositis Treatment Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent) , by Region USD Million (2018-2023)
  • Table 11. Dermatomyositis Treatment Non-Pharmacotherapy (General Therapeutic Measures, Surgery) , by Region USD Million (2018-2023)
  • Table 12. Dermatomyositis Treatment: by End User(USD Million)
  • Table 13. Dermatomyositis Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 14. Dermatomyositis Treatment Research & Development Institutes , by Region USD Million (2018-2023)
  • Table 15. Dermatomyositis Treatment Other , by Region USD Million (2018-2023)
  • Table 16. South America Dermatomyositis Treatment, by Country USD Million (2018-2023)
  • Table 17. South America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 18. South America Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 19. South America Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 20. South America Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 21. Brazil Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 22. Brazil Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 23. Brazil Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 24. Brazil Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 25. Argentina Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 26. Argentina Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 27. Argentina Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 28. Argentina Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 29. Rest of South America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 30. Rest of South America Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 31. Rest of South America Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 32. Rest of South America Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 33. Asia Pacific Dermatomyositis Treatment, by Country USD Million (2018-2023)
  • Table 34. Asia Pacific Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 35. Asia Pacific Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 36. Asia Pacific Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 37. Asia Pacific Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 38. China Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 39. China Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 40. China Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 41. China Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 42. Japan Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 43. Japan Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 44. Japan Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 45. Japan Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 46. India Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 47. India Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 48. India Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 49. India Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 50. South Korea Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 51. South Korea Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 52. South Korea Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 53. South Korea Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 54. Taiwan Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 55. Taiwan Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 56. Taiwan Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 57. Taiwan Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 58. Australia Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 59. Australia Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 60. Australia Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 61. Australia Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 66. Europe Dermatomyositis Treatment, by Country USD Million (2018-2023)
  • Table 67. Europe Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 68. Europe Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 69. Europe Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 70. Europe Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 71. Germany Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 72. Germany Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 73. Germany Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 74. Germany Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 75. France Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 76. France Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 77. France Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 78. France Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 79. Italy Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 80. Italy Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 81. Italy Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 82. Italy Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 83. United Kingdom Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 84. United Kingdom Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 85. United Kingdom Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 86. United Kingdom Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 87. Netherlands Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 88. Netherlands Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 89. Netherlands Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 90. Netherlands Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 91. Rest of Europe Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 92. Rest of Europe Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 93. Rest of Europe Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 94. Rest of Europe Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 95. MEA Dermatomyositis Treatment, by Country USD Million (2018-2023)
  • Table 96. MEA Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 97. MEA Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 98. MEA Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 99. MEA Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 100. Middle East Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 101. Middle East Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 102. Middle East Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 103. Middle East Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 104. Africa Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 105. Africa Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 106. Africa Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 107. Africa Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 108. North America Dermatomyositis Treatment, by Country USD Million (2018-2023)
  • Table 109. North America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 110. North America Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 111. North America Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 112. North America Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 113. United States Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 114. United States Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 115. United States Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 116. United States Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 117. Canada Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 118. Canada Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 119. Canada Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 120. Canada Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 121. Mexico Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2018-2023)
  • Table 122. Mexico Dermatomyositis Treatment, by Age Group USD Million (2018-2023)
  • Table 123. Mexico Dermatomyositis Treatment, by Medication Type USD Million (2018-2023)
  • Table 124. Mexico Dermatomyositis Treatment, by End User USD Million (2018-2023)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Dermatomyositis Treatment: by Dermatomyositis Type(USD Million)
  • Table 132. Dermatomyositis Treatment Classic Dermatomyositis (CDM) , by Region USD Million (2025-2030)
  • Table 133. Dermatomyositis Treatment Amyopathic Dermatomyositis (ADM) , by Region USD Million (2025-2030)
  • Table 134. Dermatomyositis Treatment Hypomyopathic Dermatomyositis (HDM) , by Region USD Million (2025-2030)
  • Table 135. Dermatomyositis Treatment Other , by Region USD Million (2025-2030)
  • Table 136. Dermatomyositis Treatment: by Age Group(USD Million)
  • Table 137. Dermatomyositis Treatment Children , by Region USD Million (2025-2030)
  • Table 138. Dermatomyositis Treatment Adults , by Region USD Million (2025-2030)
  • Table 139. Dermatomyositis Treatment: by Medication Type(USD Million)
  • Table 140. Dermatomyositis Treatment Pharmacotherapy (Corticosteroids, Immunosuppressive Agents, Immune Globulins, Antimalarial Agent) , by Region USD Million (2025-2030)
  • Table 141. Dermatomyositis Treatment Non-Pharmacotherapy (General Therapeutic Measures, Surgery) , by Region USD Million (2025-2030)
  • Table 142. Dermatomyositis Treatment: by End User(USD Million)
  • Table 143. Dermatomyositis Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 144. Dermatomyositis Treatment Research & Development Institutes , by Region USD Million (2025-2030)
  • Table 145. Dermatomyositis Treatment Other , by Region USD Million (2025-2030)
  • Table 146. South America Dermatomyositis Treatment, by Country USD Million (2025-2030)
  • Table 147. South America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 148. South America Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 149. South America Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 150. South America Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 151. Brazil Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 152. Brazil Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 153. Brazil Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 154. Brazil Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 155. Argentina Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 156. Argentina Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 157. Argentina Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 158. Argentina Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 159. Rest of South America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 160. Rest of South America Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 161. Rest of South America Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 162. Rest of South America Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 163. Asia Pacific Dermatomyositis Treatment, by Country USD Million (2025-2030)
  • Table 164. Asia Pacific Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 165. Asia Pacific Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 166. Asia Pacific Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 167. Asia Pacific Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 168. China Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 169. China Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 170. China Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 171. China Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 172. Japan Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 173. Japan Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 174. Japan Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 175. Japan Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 176. India Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 177. India Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 178. India Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 179. India Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 180. South Korea Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 181. South Korea Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 182. South Korea Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 183. South Korea Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 184. Taiwan Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 185. Taiwan Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 186. Taiwan Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 187. Taiwan Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 188. Australia Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 189. Australia Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 190. Australia Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 191. Australia Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 196. Europe Dermatomyositis Treatment, by Country USD Million (2025-2030)
  • Table 197. Europe Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 198. Europe Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 199. Europe Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 200. Europe Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 201. Germany Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 202. Germany Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 203. Germany Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 204. Germany Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 205. France Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 206. France Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 207. France Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 208. France Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 209. Italy Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 210. Italy Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 211. Italy Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 212. Italy Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 213. United Kingdom Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 214. United Kingdom Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 215. United Kingdom Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 216. United Kingdom Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 217. Netherlands Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 218. Netherlands Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 219. Netherlands Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 220. Netherlands Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 221. Rest of Europe Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 222. Rest of Europe Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 223. Rest of Europe Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 224. Rest of Europe Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 225. MEA Dermatomyositis Treatment, by Country USD Million (2025-2030)
  • Table 226. MEA Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 227. MEA Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 228. MEA Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 229. MEA Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 230. Middle East Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 231. Middle East Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 232. Middle East Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 233. Middle East Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 234. Africa Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 235. Africa Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 236. Africa Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 237. Africa Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 238. North America Dermatomyositis Treatment, by Country USD Million (2025-2030)
  • Table 239. North America Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 240. North America Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 241. North America Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 242. North America Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 243. United States Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 244. United States Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 245. United States Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 246. United States Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 247. Canada Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 248. Canada Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 249. Canada Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 250. Canada Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 251. Mexico Dermatomyositis Treatment, by Dermatomyositis Type USD Million (2025-2030)
  • Table 252. Mexico Dermatomyositis Treatment, by Age Group USD Million (2025-2030)
  • Table 253. Mexico Dermatomyositis Treatment, by Medication Type USD Million (2025-2030)
  • Table 254. Mexico Dermatomyositis Treatment, by End User USD Million (2025-2030)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dermatomyositis Treatment: by Dermatomyositis Type USD Million (2018-2023)
  • Figure 5. Global Dermatomyositis Treatment: by Age Group USD Million (2018-2023)
  • Figure 6. Global Dermatomyositis Treatment: by Medication Type USD Million (2018-2023)
  • Figure 7. Global Dermatomyositis Treatment: by End User USD Million (2018-2023)
  • Figure 8. South America Dermatomyositis Treatment Share (%), by Country
  • Figure 9. Asia Pacific Dermatomyositis Treatment Share (%), by Country
  • Figure 10. Europe Dermatomyositis Treatment Share (%), by Country
  • Figure 11. MEA Dermatomyositis Treatment Share (%), by Country
  • Figure 12. North America Dermatomyositis Treatment Share (%), by Country
  • Figure 13. Global Dermatomyositis Treatment share by Players 2023 (%)
  • Figure 14. Global Dermatomyositis Treatment share by Players (Top 3) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Ranbaxy Laboratories Limited (India) Revenue, Net Income and Gross profit
  • Figure 17. Ranbaxy Laboratories Limited (India) Revenue: by Geography 2023
  • Figure 18. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 19. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 20. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 21. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 22. Cipla Limited (India) Revenue, Net Income and Gross profit
  • Figure 23. Cipla Limited (India) Revenue: by Geography 2023
  • Figure 24. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 26. Corbus Pharmaceuticals Holdings, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Corbus Pharmaceuticals Holdings, Inc. (United States) Revenue: by Geography 2023
  • Figure 28. Global Dermatomyositis Treatment: by Dermatomyositis Type USD Million (2025-2030)
  • Figure 29. Global Dermatomyositis Treatment: by Age Group USD Million (2025-2030)
  • Figure 30. Global Dermatomyositis Treatment: by Medication Type USD Million (2025-2030)
  • Figure 31. Global Dermatomyositis Treatment: by End User USD Million (2025-2030)
  • Figure 32. South America Dermatomyositis Treatment Share (%), by Country
  • Figure 33. Asia Pacific Dermatomyositis Treatment Share (%), by Country
  • Figure 34. Europe Dermatomyositis Treatment Share (%), by Country
  • Figure 35. MEA Dermatomyositis Treatment Share (%), by Country
  • Figure 36. North America Dermatomyositis Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Ranbaxy Laboratories Limited (India)
  • Abbott Laboratories (United States)
  • Sanofi S.A. (France)
  • Cipla Limited (India)
  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Corbus Pharmaceuticals Holdings, Inc. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 160 Pages 60 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dermatomyositis Treatment Market Quantitative research analysis
Global Dermatomyositis Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Ranbaxy Laboratories Limited (India), Abbott Laboratories (United States), Sanofi S.A. (France), Cipla Limited (India), Actelion Pharmaceuticals Ltd. (Switzerland) and Corbus Pharmaceuticals Holdings, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Skin And Muscles Diseases Among Adults" is seen as one of major influencing trends for Dermatomyositis Treatment Market during projected period 2023-2030.
The Dermatomyositis Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Dermatomyositis Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Nonseminomatous Testicular Cancer Comprehensive Study by Treatment (Surgical, Non-surgical), Stages (Stage 0, Stage I (IA, IB, IS), Stage II (IIA, IIB, IIC), Stage III (IIIA, IIIB, IIIC)), Cancer Typ...
$ 3650
Companion Animal Health Management Comprehensive Study by Type (Diagnosis, Pharmaceuticals & Treatment, Vaccination, Nutrition & Supplement, Others), Application (Veterinary Hospitals & Clinics, In-h...
$ 3800
Healthcare Contact Center Solution Comprehensive Study by Type (Omnichannel Routing, Workforce Engagement Management, Reporting And Analytics, Customer Engagement Management, Others), Application (Pu...
$ 3450
Healthcare CRO Services Comprehensive Study by Type (Early Phase Development Services {Discovery Studies, Chemistry, Manufacturing & Control, Preclinical Services (Pharmacokinetics /Pharmacodynamics,...
$ 3750
Rapid Microbiology Testing Comprehensive Study by Application (Clinical Disease Diagnosis, Food & Beverage Testing, Pharmaceutical & Biological Drug Testing, Cosmetics & Personal Care Products Testin...
$ 3750
Travel Nursing Staffing Comprehensive Study by Type (Temporary, Permanent), Service (Examining Patients, Labor & Delivery, Critical Care / ICU, Operating Room, Emergency Room, Telemetry, Others), End...
$ 3450